首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1619107

連網型給藥設備市場規模、佔有率、成長分析、按產品類型、按技術、按應用、按最終用戶、按地區 - 行業預測，2024-2031 年

Connected Drug Delivery Devices Market Size, Share, Growth Analysis, By Product Type (Connected Inhalers, Metered Dose Inhalers (MDIs)), By Technology (Bluetooth, Wi-Fi), By Application, By End-User, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月17日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022 年，連網型給藥設備的全球市場規模為 3.479 億美元，從 2023 年的 4.3348 億美元成長到 2031 年的 25.1835 億美元，預計在預測期內（2024 年~2031 年）將會成長。成長率為24.6%。

在數位健康解決方案的普及和個人化醫療需求不斷成長的推動下，全球連網型給藥設備市場有望顯著成長。這些創新設備為患者和看護者提供即時資料追蹤、提醒和通知，以改善藥物管理和患者治療結果。物聯網、人工智慧和雲端運算等先進技術正在改變藥物傳輸系統，促進增強病人參與並促進遠端監控。隨著醫療保健系統優先考慮數位轉型和以患者為中心的方法，以及醫療保健服務的轉變擴大採用技術整合以改善患者體驗和結果，該市場預計將顯著擴大。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2023）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2021-2023）

主要企業簡介

Findair Sp. z oo（Poland）
BIO CORP（France）
Teva Pharmaceuticals Industries Ltd（Israel）
Adherium Limited（New Zealand）
West Pharmaceutical Services Inc.（USA）
Aptar Pharma（USA）
Ypsomed AG（Switzerland）
Phillips-Medisize（USA）
H&T Presspart Manufacturing Ltd（UK）
Cohero Health, Inc.（USA）
3M Company（USA）
Becton, Dickinson and Company（USA）
Merck KGaA（Germany）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
AstraZeneca（UK）
GlaxoSmithKline plc（UK）
Pfizer Inc.（USA）
Sanofi SA（France）
F. Hoffmann-La Roche Ltd（Switzerland）

結論和建議

簡介目錄

Product Code: SQMIG35G2246

Global Connected Drug Delivery Devices Market size was valued at USD 347.9 million in 2022 and is poised to grow from USD 433.48 million in 2023 to USD 2518.35 million by 2031, growing at a CAGR of 24.6% during the forecast period (2024-2031).

The global connected drug delivery devices market is poised for significant growth, fueled by the rising adoption of digital health solutions and the demand for personalized healthcare. These innovative devices provide real-time data tracking, reminders, and notifications for patients and caregivers, improving medication management and patient outcomes. Advanced technologies like IoT, AI, and cloud computing are transforming drug delivery systems, fostering enhanced patient engagement and facilitating remote monitoring. As healthcare systems prioritize digital transformation and patient-centric approaches, the market is set to expand substantially, reflecting a shifting landscape in healthcare delivery that increasingly embraces technological integration for better patient experiences and outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Connected Drug Delivery Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Connected Drug Delivery Devices Market Segmental Analysis

Global Connected Drug Delivery Devices Market is segmented by product type, technology, application, end-user and region. Based on product type, the market is segmented into connected inhalers, connected injection devices and connected monitoring devices. Based on technology, the market is segmented into bluetooth, wi-fi, near field communication (NFC) and others. Based on application, the market is segmented into diabetes, asthma & COPD, cardiovascular diseases and other. Based on end-user, the market is segmented into hospitals, homecare settings and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Connected Drug Delivery Devices Market

A significant driver for the global connected drug delivery devices market is the rising demand for personalized and interconnected healthcare solutions. These innovative devices provide numerous advantages, including remote patient tracking, real-time data collection, and enhanced medication adherence. By allowing healthcare professionals to monitor patient health continuously, they can adjust treatment plans accordingly and deliver tailored care. Furthermore, the incorporation of connected technologies into drug delivery systems fosters greater patient engagement and leads to improved treatment outcomes. The escalating incidence of chronic diseases and the increasing need for sophisticated drug delivery mechanisms also play essential roles in propelling the growth of this market.

Restraints in the Global Connected Drug Delivery Devices Market

A major constraint facing the global connected drug delivery devices market is the substantial cost linked to these advanced technologies. These devices incorporate intricate components such as wireless connectivity and sophisticated data management systems, which collectively contribute to elevated pricing. Such financial implications can hinder widespread acceptance, especially in low-resource environments and developing countries, where budgetary limitations are critical. This cost-related barrier restricts the availability and use of connected drug delivery devices among various patient demographics and healthcare frameworks. To facilitate broader market growth and enhance adoption rates, it is crucial to tackle affordability issues effectively.

Market Trends of the Global Connected Drug Delivery Devices Market

The global connected drug delivery devices market is witnessing a significant trend towards the adoption of smart inhalers and connected devices, especially for respiratory therapies. These advanced devices leverage sensors, wireless connectivity, and mobile applications to facilitate comprehensive tracking of medication usage, dosage accuracy, and patient adherence. The incorporation of digital technologies not only enables real-time data collection and remote monitoring but also supports personalized treatment plans tailored to individual patient needs. This trend fosters enhanced patient engagement and empowerment, as users gain valuable insights and feedback on their medication habits, ultimately driving improved health outcomes and ensuring greater adherence to treatment protocols.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Patent Analysis
Case Studies
Startup Analysis

Global Connected Drug Delivery Devices Market Size by Product Type & CAGR (2024-2031)

Market Overview
Connected Inhalers
- Metered Dose Inhalers (MDIs)
- Dry Powder Inhalers (DPIs)
Connected Injection Devices
- Connected Auto-Injectors
- Connected Pen Injectors
- Connected Wearable Injectors
Connected Monitoring Devices
- Smart Pills
- Smart Patches

Global Connected Drug Delivery Devices Market Size by Technology & CAGR (2024-2031)

Market Overview
Bluetooth
Wi-Fi
Near Field Communication (NFC)
Others

Global Connected Drug Delivery Devices Market Size by Application & CAGR (2024-2031)

Market Overview
Diabetes
- Insulin Delivery
Asthma & COPD
- Bronchodilator Delivery
Cardiovascular Diseases
- Anticoagulant Delivery
Other
- Hormone Replacement Therapy
- Pain Management

Global Connected Drug Delivery Devices Market Size by End-User & CAGR (2024-2031)

Market Overview
Hospitals
- Large Hospitals
- Small and Medium-Sized Hospitals
Homecare Settings
- Individual Patients
- Caregivers
Clinics
- Specialty Clinics
- General Clinics

Global Connected Drug Delivery Devices Market Size & CAGR (2024-2031)

North America (Product Type, Technology, Application, End-User)
- USA
- Canada
Europe (Product Type, Technology, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Technology, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Technology, Application, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Technology, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Findair Sp. z o. o. (Poland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BIO CORP (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adherium Limited (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
West Pharmaceutical Services Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptar Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ypsomed AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Phillips-Medisize (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H&T Presspart Manufacturing Ltd (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cohero Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
3M Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments